Atypical mycobacteria keratitis after laser in situ keratomileusis unresponsive to fourth-generation fluoroquinolone therapy.
We report a case of post-laser in situ keratomileusis atypical mycobacteria infection unresponsive and resistant to fourth-generation fluoroquinolones, which highlights the importance of a high level of suspicion and the need for multidrug therapy for effective eradication.
de la Cruz
Jose
J
Cornea and Refractive Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
Behlau
Irmgard
I
Pineda
Roberto
R
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D015818:Eye Infections, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D024841:Fluoroquinolones / Q000627:therapeutic use*; D000077734:Gatifloxacin; D006801:Humans; D007634:Keratitis / Q000188:drug therapy* / Q000382:microbiology; D020731:Keratomileusis, Laser In Situ; D008297:Male; D008826:Microbial Sensitivity Tests; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology; D016926:Mycobacterium chelonae / Q000187:drug effects* / Q000302:isolation & purification; D009216:Myopia / Q000601:surgery; D013524:Surgical Flaps / Q000382:microbiology; D013530:Surgical Wound Infection / Q000188:drug therapy* / Q000382:microbiology
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D017291:Clarithromycin; D000077734:Gatifloxacin